Fig. 6.
Anti-TSLP antibody treatment only partially inhibits allergic inflammation in contrast to CRTH2 antagonism. One hour prior to FITC challenge, mice received drug Veh p.o., drug Veh p.o. and 500 μg control antibody intravenously (i.v.), Cmpd A (1 mg kg−1) p.o., Cmpd A (0.1 mg kg−1) and control antibody i.v., anti-TSLP antibody (500 μg) i.v. and Cmpd A (0.1 mg kg−1) p.o. and anti-TSLP antibody i.v. Seven hours after FITC challenge to the right ear, the appropriate groups received either drug Veh or Cmpd A p.o. (A) Twenty-four hours after challenge, ear thickness was determined and the change in thickness calculated. (B) Ear sections isolated 24 h after FITC challenge were stained with H and E. Protein lysates from the treated ears were assayed for IL-4 (C) and GRO-α (D). Fifty micrograms of total protein from lysates were analyzed by ELISA. The results show the mean cytokine levels ± SEM of a minimum of five mice per treatment group.